Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators

Journal of Surgical Oncology

Volumn 62, Issue 2, 1996, Pages 86-92

  Patel, Devendra D ^a   Bhatavdekar, Jyotsna M ^a   Chikhlikar, Priya R ^a   Ghosh, Nandita ^a   Suthar, Tejal P ^a   Shah, Neelam G ^a   Mehta, Ranna H ^a   Balar, Damodar B ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

c erbB2; cathepsin D; estrogen receptor; nm23; p53; plasma prolactin; progesterone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN D; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROLACTIN; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METASTASIS; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; CYTOSOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; NUCLEOSIDE-DIPHOSPHATE KINASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLACTIN; RADIOIMMUNOASSAY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0029948890     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199606)62:2<86::AID-JSO3>3.0.CO;2-M     Document Type: Article

References (32)

1. McGuire WL, Tandon AK, Allred DC, et al.: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990.
2. Bhatavdekar JM, Shah NG, Balar DB, et al.: Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 65:2028-2032, 1990.
3. Bhatavdekar JM, Patel DD, Karelia NH, et al.: The clinical significance of prolactin, TPS, CA 15-3 and CEA in patients with breast cancer. Breast Dis 6:177-183, 1993.
4. Bhatavdekar JM, Patel DD, Sherbet GV, et al.: Prognostic significance of plasma prolactin in breasl cancer: Comparison with the expression of c-erbB-2 oncoprotein. Eur J Surg Oncol 19:409-413, 1993.
5. Allred DC, Clark GM, Elledge R, et al.: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993.
6. Gasparini G, Weidner N, Bevilacqua P, et al.: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994.
7. Porter-Jordan K, Lippman ME: Overview of the biologic markers of breast cancer. In Shapiro CL, Henderson IC (Guest eds): "Hematology/Oncology Clinics of North America." Philadelphia: WB Saunders, 1994, p 73-100.
8. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993.
9. Breast (ICD-0 T-174), UICC: TNM Classification of Malignant Tumors. 1st ed. Geneva: UICC International Union Against Cancer, 1980.
10. Bhatavdekar JM, Patel DD, Giri DD, et al.: Plasma prolactin and prognosis in advanced breast cancer. Breast Dis 6:107-111, 1993.
11. Bhatavdekar JM, Trivedi SN, Shah NG, et al.: Correlation of steroid receptors with histopathologic characteristics in breast carcinoma. Neoplasma 35:413-423, 1988.
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275, 1951.
13. Mehta CR, Patel NR: A network algorithm for Fisher's exact test in RxC contingency tables. J Amer Stat Assn 78:427-434, 1983.
14. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Amer Stat Assn 53:457-481, 1958.
15. Pearson ES, Hartley HO: Approximate significance tests for contingency tables. In Matthews DE, Farewell VT (eds): "Using and Understanding Medical Statistics." Switzerland: S. Karger AG, 1988, p 39-53.
16. Bhatavdekar JM, Patel DD, Vora HH, et al.: Comparison of the prognostic value of plasma prolactin with that of receptors for prolactin, epidermal growth factor, estrogen, and progesterone in patients with stage III breast cancer. Breast Dis 8:319-326, 1995.
17. Ward HW: Combined anti-prolactin and anti-oestrogen therapy for breast carcinoma. Clin Oncol 3:91-95, 1977.
18. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88:5006-5010, 1991.
19. Shaulsky G, Ben-Ze'ev A, Rotter V: Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5:1701-1711, 1990.
20. Cattoretti G, Andreola S, Clemente C, et al.: Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer 57:353-357, 1988.
21. Ostrowski JL, Sawan A, Henry L, et al.: p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 164:75-81, 1991.
22. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS: Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989.
23. Sawan A, Lascu I, Veron M, et al.: NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J Pathol 172:27-34, 1994.
24. Gasparini G, Gullick WJ, Bevilacqua P, et al.: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992.
25. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992.
26. Spyratos F, Maudelonde T, Brouillet JP, et al.: Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet 2:1115-1118, 1989.
27. Kute TE, Shao ZM, Sugg NK, et al.: Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52:5198-5203, 1992.
28. Namer M, Ramaioli A, Fontana X, et al.: Prognostic value of total cathepsin D in breast tumors: A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19:85-93, 1991.
29. Pujol P, Maudelonde T, Daures JP, et al.: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71:2006-2012, 1993.
30. Granata G, Coradini D, Cappelletti V, Di-Fronzo G: Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer 27:970-972, 1991.
31. Duffy MJ, Brouillet JP, Reilly D, et al.: Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem 37:101-104, 1991.
32. Ravdin PM: Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24:219-226, 1993.